1. Repligen launched three new high-performance chromatography resins for gene therapy. 2. The AVIPure® HiPer™ AAV8 and AAV9 resins enhance processing and product development. 3. These advancements strengthen Repligen's leadership in bioprocessing technologies. 4. The new products are designed for today’s complex biotherapeutic workflows. 5. Broader chromatography resin launches are anticipated in 2026.
FAQ
Why Bullish?
The launch of new products positions RGEN for growth, similar to past successful releases.
How important is it?
The innovation in chromatography resins could significantly boost RGEN's market share and revenue.
Why Long Term?
The new product lines will benefit RGEN's positioning as overall bioprocessing demand rises.
Repligen Launches Innovative Chromatography Resins to Enhance Bioprocessing
WALTHAM, Mass., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a leader in bioprocessing technology, has announced the introduction of three cutting-edge chromatography resins: AVIPure® HiPer™ AAV9, AVIPure® HiPer™ AAV8 affinity resins, and HiPer™ QA anion exchange resin. This product launch marks a significant expansion of the company's proteins portfolio and demonstrates Repligen's ongoing commitment to advancing next-generation bioprocessing solutions.
Performance Innovations for New Modalities
The newly developed HiPer resins are based on the innovative Tantti™ DuloCore™ base bead technology. They are designed to provide superior performance for emerging modalities such as viral vectors. By enhancing process economies and product stability, these resins enable gene therapy developers to accelerate their product development timelines and achieve faster market access.
Expanding Leadership in Bioprocessing
As demand for innovative bioprocessing solutions grows, Repligen continues to deliver the tools necessary for success in the biotechnology sector. The release of these new resins enhances the company's reputation for process productivity and prepares customers for broader chromatography resin launches anticipated in 2026. Umay Saplakoğlu, Vice President of Proteins and Incubator at Repligen, stated, “These new resins further expand our growing proteins portfolio with purpose-built, next-generation tools that leverage both our AVIPure® affinity ligands and HiPer™ bead technologies.”
- AVIPure® HiPer™ AAV9 and AAV8 targeted at gene therapy manufacturers.
- HiPer™ QA anion exchange resin for enhanced workflow efficiency.
- Robust performance for complex biotherapeutic processes.
About Repligen Corporation
Repligen Corporation stands as a pioneering global life sciences company specialized in the development and commercialization of advanced bioprocessing technologies. The company aims to drive efficiencies in the production of biological drugs and is dedicated to inspiring advances in bioprocessing for biopharmaceutical developers and contract manufacturing organizations (CDMOs) worldwide. With its headquarters located in Waltham, Massachusetts, Repligen operates numerous manufacturing sites across the U.S. as well as in Estonia, France, Germany, Ireland, the Netherlands, and Sweden.